Subscribe
logo-tag-line
Courtesy of Aurobindo Pharma
4 July 2014Americas

Aurobindo sued by Pfizer over skin antibiotic

Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Biofrontera settles patent dispute with Dusa over skin treatment
30 November 2021   A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
Americas
Pfizer to settle Xeljanz suit with Teva
9 September 2021   Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Americas
Biofrontera settles patent dispute with Dusa over skin treatment
30 November 2021   A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
Americas
Pfizer to settle Xeljanz suit with Teva
9 September 2021   Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

More on this story

Americas
Biofrontera settles patent dispute with Dusa over skin treatment
30 November 2021   A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
Americas
Pfizer to settle Xeljanz suit with Teva
9 September 2021   Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.
Big Pharma
Pfizer sues India generic drugmaker over cancer drug
14 January 2021   Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory